Search

A recent study conducted by researchers at Erasmus University Medical Center in Rotterdam, Netherlands, explored the relationship between thiazide diuretics, urinary prostaglandin E2 (PGE2) excretion, and serum sodium levels in the general population. The study found that higher urinary PGE2 excretion was associated with lower serum sodium levels, and this association was stronger in individuals taking thiazide diuretics. The researchers suggest that PGE2-mediated water reabsorption may play a role in regulating serum sodium levels and could be relevant to the development of hyponatremia, particularly thiazide-induced hyponatremia. Further research is needed to fully understand the mechanisms involved. [Extracted from the article]

A recent study conducted by researchers at China Medical University and Hospital examined the prescribing cascades of antigout medications in gout-naive hypertensive adults who were receiving first-line pharmacological management. The study utilized a retrospective cohort design and analyzed data from the Taiwan National Health Insurance Registry Database. The findings revealed that gout-naive hypertensive adults who were prescribed thiazide diuretics had a higher risk of subsequently being prescribed antigout agents compared to those taking other first-line antihypertensive medications. The researchers emphasized the importance of awareness and intervention to improve patient safety in these prescribing cascades. [Extracted from the article]

A report from Columbia University Medical Center discusses the comparative safety and effectiveness of angiotensin converting enzyme inhibitors (ACEi) and thiazides and thiazide-like diuretics as monotherapy for hypertension. Previous studies showed more favorable outcomes for thiazides, but this study modified the definition of monotherapy to exclude the addition of another antihypertensive medication. The results indicate that there is a less striking difference in effectiveness between ACEi and thiazides, although the safety profile of thiazides remains more favorable. This research has been peer-reviewed and provides valuable insights into the treatment of hypertension. [Extracted from the article]

A recent study conducted by researchers at the Statens Serum Institute in Copenhagen, Denmark, aimed to estimate the cumulative incidence of thiazide-induced hyponatremia compared to nonthiazide antihypertensive drugs in routine clinical practice. The study found that treatment initiation with thiazide diuretics posed a higher risk for hyponatremia, particularly during the first months of treatment, than indicated by drug labeling. The risk differences were higher in older individuals and those with a higher comorbidity burden. However, the study had limitations, including the assumption that filled prescriptions equaled drug use and the likelihood of residual confounding. Primary funding for the research came from Det Frie Forskningsrad (DFF) and the Independent Research Fund Denmark. [Extracted from the article]

Inventors Stephen MacMahon and Anthony Rodgers have filed a patent application for a new treatment for hypertension. The application describes a pharmaceutical composition that includes an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker. The composition aims to reduce blood pressure and improve tolerability, with doses ranging from 40% to 80% of the lowest therapeutic dose for each component. The inventors suggest that this new treatment could address the issue of poor blood pressure control and the need for more effective and well-tolerated options. The patent also includes methods of treating hypertension and dyslipidemia using these compositions. [Extracted from the article]

Keywords: Lagos; Nigeria; Africa; Amides; Aromatic Hydrocarbons; Benzene Derivatives; Benzothiadiazines; Cancer; Colon Cancer; Health and Medicine; Hydrocarbons; Nitro Compounds; Nitrobenzenes; Oncology; Organic Chemicals; Sulfonamides; Sulfur Compounds; Thiazides EN Lagos Nigeria Africa Amides Aromatic Hydrocarbons Benzene Derivatives Benzothiadiazines Cancer Colon Cancer Health and Medicine Hydrocarbons Nitro Compounds Nitrobenzenes Oncology Organic Chemicals Sulfonamides Sulfur Compounds Thiazides 1183 1183 1 09/19/23 20230922 NES 230922 2023 SEP 19 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Oncology - Colon Cancer. Lagos, Nigeria, Africa, Amides, Aromatic Hydrocarbons, Benzene Derivatives, Benzothiadiazines, Cancer, Colon Cancer, Health and Medicine, Hydrocarbons, Nitro Compounds, Nitrobenzenes, Oncology, Organic Chemicals, Sulfonamides, Sulfur Compounds, Thiazides Keywords for this news article include: Lagos, Nigeria, Africa, Amides, Aromatic Hydrocarbons, Benzene Derivatives, Benzothiadiazines, Cancer, Colon Cancer, Health and Medicine, Hydrocarbons, Nitro Compounds, Nitrobenzenes, Oncology, Organic Chemicals, Sulfonamides, Sulfur Compounds, Thiazides, University of Lagos. [Extracted from the article]

The NCC has a major role in salt reabsorption in the distal convoluted tubule of the nephron(2,3), and mutations in the NCC cause the salt-wasting disease Gitelman syndrome(4)." Keywords: Stanford; State:California; United States; North and Central America; Genomics and Genetics; Sulfur Compounds; Thiazides EN Stanford State:California United States North and Central America Genomics and Genetics Sulfur Compounds Thiazides 600 600 1 04/03/23 20230407 NES 230407 2023 APR 7 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Genomics and Genetics. Funders for this research include National Institutes of Health (NIH) - USA, Harold and Leila Y. Mathers Charitable Foundation, National Institutes of Health (NIH) - USA. [Extracted from the article]